This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bear of the Day: NuVasive (NUVA)
by Kevin Cook
Another earnings hiccup puts this spinal surgery innovator back in the cellar of the Zacks Rank
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
New Strong Buy Stocks for April 11th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Mazor Robotics Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Mazor Robotics (MZOR) gains from flagship Mazor X performance and soaring system orders.
The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom
4 MedTech Stocks to Explode in 2018
by Zacks Equity Research
Standing at the threshold of 2018 it is imperative for the investors to find the means which can dilute the macroeconomic woes and help them gain more.
Mazor Projects Higher Q3 Revenues, Clinches Mazor X Orders
by Zacks Equity Research
Mazor's (MZOR) strong booking and order backlog from Mazor X system sales is likely to boost fortunes in the global spine surgery space.
Company News For Oct 10, 2017
by Zacks Equity Research
Companies in the news are: MZOR,CGEN,KTWO,AXTA
Should You Buy Mazor Robotics (MZOR) As It Hits New High?
by Benjamin Rains
Shares of Mazor Robotics (MZOR) surged over 5% on Wednesday to touch a new all-time high. Now the question for investors is: should you consider buying the surgical robotics maker's stock?
Mazor Robotics Gets CE Mark for Surgical Assurance Platform
by Zacks Equity Research
Earlier this year, Mazor Robotics (MZOR) had announced the receipt of FDA clearance for its Mazor X Align software.
Mazor Robotics' CE Mark for Mazor X Platform to Drive Orders
by Zacks Equity Research
Mazor Robotics and Medtronic will now be able to market and sell the Mazor X Surgical Assurance Platform in countries that recognize the CE Mark.
Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now
by Zacks Equity Research
The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.
4 Momentum Stocks to Pick Despite MedTech Policy Debacle
by Zacks Equity Research
Investors might pay heed to Zacks counsel and hitch the momentum ride to tide over the Obamacare debacle.
Mazor Robotics Hits 52-Week High Through Medtronic Alliance
by Zacks Equity Research
Mazor Robotics (MZOR) touched a new 52-week high on the back of favorable amendment of its strategic partnership with Medtronic.
Mazor Expects Higher Q2 Revenues, Wins Mazor X Orders
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR), recently announced that it expects to report second-quarter 2017 revenue of approximately $15.4 million compared with $8.3 million from the year-ago quarter.
Is the Options Market Predicting a Spike in Mazor Robotics (MZOR) Stock?
by Zacks Equity Research
Mazor Robotics (MZOR) needs Investors to pay close attention to the stock based on moves in the options market lately.
Mazor Robotics at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Shares of Israel-based developer of robotic technology and products, Mazor Robotics Ltd. (MZOR), rallied to a new 52-week high of $45.64 on May 18.
Mazor (MZOR) Gets FDA Clearance For Mazor X Align Software
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR), recently announced that it has received the FDA clearance for its Mazor X Align software.
Mazor Robotics (MZOR) Catches Eye: Stock Moves Up 10.2%
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR) moved big last session, as its shares rose over 10% on the day.
Mazor Expects Higher Q1 Revenue, Receives Mazor X Orders
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR), recently announced that it expects to report record first-quarter 2017 revenue of approximately $11.5 million compared with only $6.4 million in the year-ago quarter.
Mazor Robotics-Medtronic's Mazor X Partnership Strengthens
by Zacks Equity Research
Mazor Robotics (MZOR) recently announced that its strategic partnership with Medtronic Plc. (MDT) for the commercialization and co-promotion of Mazor X platform, an innovative guidance system for spine surgery, is going strong.
Mazor Robotics (MZOR) Receives 21 System Orders in Q4
by Zacks Equity Research
Israel-based developer of robotic technology and products, Mazor Robotics Ltd. (MZOR), recently announced the receipt of 21 surgical guidance system orders in fourth-quarter 2016.
Mazor Robotics Receives Order for Three Mazor X Systems
by Zacks Equity Research
Israel-based developer of robotic technology and products, Mazor Robotics Ltd. (MZOR), recently announced a three-system order for the Mazor X, from a leading mid-Atlantic health care organization.